Clinical trial
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and…
NCT00112021 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00112021 |
|---|---|
| Title | A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects |
| Official title | A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | pramlintide acetate |
| Enrollment | 400 |
| Start date | May 1, 2005 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | May 30, 2005 |
| Last update posted | Apr 10, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: